Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
27 Feb, 20:00
NYSE NYSE
$
248. 43
+4.96
+2.04%
$
584.38B Market Cap
29.06 P/E Ratio
1.34% Div Yield
16,328,515 Volume
9.91 Eps
$ 243.47
Previous Close
Day Range
242.5 248.93
Year Range
141.5 248.94
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
JNJ earnings report is expected in 44 days (13 Apr 2026)
2 Healthcare Stocks to Buy Hand Over Fist This Month

2 Healthcare Stocks to Buy Hand Over Fist This Month

Johnson & Johnson and Medtronic are healthcare leaders that have faced their share of issues in recent years. Still, both companies have the innovative capabilities and expertise to succeed in the industry in the long run.

Fool | 1 year ago
3 Key Earnings Reports to Watch Next Week

3 Key Earnings Reports to Watch Next Week

With the 2024 Q2 earnings season kicking into a much higher gear next week, there are several reports investors should keep on their radars, including these three.

Zacks | 1 year ago
Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics

Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics

Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks | 1 year ago
3 Essential Stocks for Building a Recession-Proof Portfolio

3 Essential Stocks for Building a Recession-Proof Portfolio

Recession-proof stocks offer investors a safe harbor to shield their portfolios from downside risk. The stock market has cooled off following its AI-powered surge for the last two years.

Investorplace | 1 year ago
Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality

Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality

Johnson & Johnson will announce its Q2 2024 results on Wednesday, July 17 before the market opens. In this update, I share what to expect from JNJ's Q2 results and put previous results into perspective. In the main part of the article, I will take a close look at JNJ's earnings adjustments, amid the significant deviation from GAAP earnings (+46% median since 2014).

Seekingalpha | 1 year ago
3 Undervalued Stocks Set to Outperform the Market in 2024

3 Undervalued Stocks Set to Outperform the Market in 2024

During stock investing, having a list of the top undervalued stocks can offer lucrative opportunities for value growth and portfolio stability. Here are three stocks whose intrinsic value exceeds their current market price, promising potential gains as the market corrects itself.

Investorplace | 1 year ago
AI picks 3 must-have dividend stocks for 2024 H2

AI picks 3 must-have dividend stocks for 2024 H2

In an era where some investors prioritize stable income and reliable returns, artificial intelligence (AI) has identified three standout dividend stocks poised to shine in the latter half of 2024.

Finbold | 1 year ago
7 Diversified Income Powerhouses for Lifelong Cash Flow

7 Diversified Income Powerhouses for Lifelong Cash Flow

Diversified income stocks are a smart choice for investors seeking lifelong cash flow. They offer a reliable stream of income from multiple sources and provide stability and growth potential in any market condition.

Investorplace | 1 year ago
Johnson & Johnson: Remaining A Buy Despite Remaining Risks

Johnson & Johnson: Remaining A Buy Despite Remaining Risks

Johnson & Johnson reported solid first quarter results and is also expecting mid-single digit growth for the full year. The company is facing risks right now, especially from the litigations due to the talc products, and breaking the support line is also a rather bearish sign. But the stock seems slightly undervalued at this point, and Johnson & Johnson is probably a good investment for investors seeking stability and a bond-like investment.

Seekingalpha | 1 year ago
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?

J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?

A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.

Zacks | 1 year ago
Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return

Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return

Johnson & Johnson's underlying business has a stable long-term outlook and the stock has a low volatility profile, which makes it an ideal platform for selling put options. The company is trading at a highly attractive valuation, which provides a solid margin of error. Selling put options does sacrifice capital appreciation, but with a nearly 10% annualized yield on offer, this opportunity appears to be a win-win to us.

Seekingalpha | 1 year ago
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off

2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off

Dividends can boost your portfolio returns. Johnson & Johnson is a classic example of a value stock with a faithful dividend history.

Fool | 1 year ago
Loading...
Load More